Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Retained Earnings (2018 - 2025)

Historic Retained Earnings for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$570.6 million.

  • X4 Pharmaceuticals' Retained Earnings fell 1999.75% to -$570.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$570.6 million, marking a year-over-year decrease of 1999.75%. This contributed to the annual value of -$515.4 million for FY2024, which is 783.63% down from last year.
  • As of Q3 2025, X4 Pharmaceuticals' Retained Earnings stood at -$570.6 million, which was down 1999.75% from -$540.8 million recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Retained Earnings peaked at -$212.9 million during Q1 2021, and registered a low of -$570.6 million during Q3 2025.
  • Over the past 5 years, X4 Pharmaceuticals' median Retained Earnings value was -$438.8 million (recorded in 2024), while the average stood at -$406.1 million.
  • In the last 5 years, X4 Pharmaceuticals' Retained Earnings tumbled by 4863.9% in 2021 and then surged by 386.9% in 2024.
  • Over the past 5 years, X4 Pharmaceuticals' Retained Earnings (Quarter) stood at -$282.9 million in 2021, then crashed by 33.18% to -$376.7 million in 2022, then decreased by 26.85% to -$477.9 million in 2023, then decreased by 7.84% to -$515.4 million in 2024, then decreased by 10.73% to -$570.6 million in 2025.
  • Its last three reported values are -$570.6 million in Q3 2025, -$540.8 million for Q2 2025, and -$515.1 million during Q1 2025.